IMUC is a clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers.

1. Manish Singh, PhD
President and CEO
OTC BB: IMUC.OB
www.imuc.com
January 2010 1

2. SEC Disclaimer Statement
This presentation contains certain “forward‐looking statements”
(statements as to matters other than historical facts) as defined in
the Private Securities Litigation Reform Act and in Section 27A of
the Securities Act of 1933 and Section 21E of the Securities
Exchange Act of 1934. Such statements involve risks and
uncertainties that could cause actual events or results to differ
materially from the events, projections or results described in the
forward‐looking statements. These risks and uncertainties are
described in IMUC’s most recently filed SEC documents, such as its
most recent annual report on Form 10‐K, all quarterly reports on
Form 10‐Q and any current reports on Form 8‐K.
January 2010 2

3. Mission
To develop new immune‐based products to target
cancer stem cells
January 2010 3

4. Cancer Stem Cells: Good Guys Turned Bad
Progenitor cells
Normal
Stem Cell • Cancers originate in tissue
Mature progenitor cells or normal
Tissue
stem cells through
dysregulation of the self‐
mutations renewal process
• Throughout tumorigenesis
CSCs drive tumor growth
Bulk
Tumor
Cancer
Stem Cell
Targeting CSCs may significantly delay or prevent
disease recurrences.
January 2010 4

5. Technology Overview:
Utilizing Both Arms of Immune System
ACTIVE IMMUNOTHERAPIES
Cellular Vaccine (ICT‐107)
• Dendritic cell‐based vaccine to elicit persistent and targeted
T cell immune response against tumor‐associated /CSC antigens
• Phase I trial recently completed in glioblastoma multiforme
CSC Antigen Vaccine (ICT‐121)
• Platform technology for cancer stem cells
• Peptide‐based, off‐the‐shelf vaccine (peptide plus adjuvant)
• IND to be filed in second half of 2010
ANTIBODY IMMUNOTHERAPIES
• Antibody therapeutics targeting novel cancer antigens and cancer
stem cells
• DIAAD: platform technology for cancer antigens
January 2010 5

6. ICT‐107: Dendritic Cell‐Based Vaccine Targeting Cancer
Stem Cells and Tumor Associated Antigens
Antigens Tumor Expression CSC
Expression
gp100 Melanoma, brain cancer
Trp‐2 Melanoma and brain cancer High
Her‐2/neu Breast, ovarian cancer Medium
MAGE‐1 Melanoma, brain cancer
AIM Breast, ovarian, colon, brain High
IL‐13aR2 Brain cancer
January 2010 6

7. Significant Improvement in Progression‐Free Survival
(Compared to Historical Controls Using Standard of Care)
Radiation + Temozolomide* Radiation + Temozolomide +ICT-107
•Stupp et al, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma,
New England Journal of Medicine, March 2005
January 2010 7

8. Summary of Clinical Data:
Progression‐Free and Overall Survival
Newly Diagnosed (16) SOC + Historical
ICT‐107 Control
(SOC)
Median PFS (months) 19.0 6.9
Median OS (months) > 21 14.2
% Survival at 12 months 94% 60%
% Survival at 21 months 80% 30%
Recurrent (3)
Median OS (months) 30.5 7.0 (9.2 with
Avastin+SO
C)
SOC = Standard of care (surgery + radiation + Temozolomide)
January 2010 8

9. ICT‐121: Cancer Stem Cell Vaccine
• Peptide‐based vaccine targeting CD133 antigen
present on CSCs
• Initial indication in glioblastoma
• Off‐the‐shelf, peptide‐based vaccine
• IND to be filed in H2 2010
• May also be applicable to pancreatic, lung, colon,
renal, melanoma, and breast cancers
• Only company developing an active immunotherapy
platform targeting CSCs
Potential Blockbuster Product
January 2010 9

10. Summary of Antibody Programs
• ICT‐109: Antibody targeting small‐cell
lung cancer and pancreatic cancers
• High affinity (10‐100 fold higher)
• Humanized
• In‐vivo and in‐vitro efficacy
• ICT‐69: Multiple myeloma and ovarian
cancer
• Novel target
• In‐vivo and in‐vitro efficacy
• License option agreement with Roche
• CSC Antibodies: Under development using
proprietary CSC lines
January 2010 10

11. Value Creation Catalysts in Next 12 Months
• Clinical
• Initiate Phase II clinical trials for ICT‐107 (H2 2010)
• IND filing for ICT‐121 for glioblastoma in US (H2 2010)
• Regulatory
• Orphan Drug Application for ICT‐107 (H1 2010)
• Business Development
• Potential partnering of ICT‐107 and/or ICT‐109 in 2010
• Additional Roche licensing payments for ICT‐69 in 2010
January 2010 11

12. Management Team
• Manish Singh, PhD, President and CEO
• California Technology Ventures, Cell Genesys, Chiron‐Viagene,
Genetic Therapy Inc (Novartis)
• John Yu, MD, Chairman and CSO
• Neurosurgeon at Cedars‐Sinai Medical Center, Mass General
Hospital, Harvard Medical School
• Jim Bender, PhD, MPH, VP of Clinical Development
• IDM Pharma, Baxter Healthcare
• C. Kirk Peacock, CPA, CFO
• CytRx, DigitalMed, Ants.com
January 2010 12

13. Key Opinion Leaders
• Keith Black, MD, Head of Scientific Advisory Board
Head of Neurosurgery, Cedars‐Sinai Medical Center
• George Peoples, MD, Member of Scientific Advisory Board
Director of Cancer Vaccines, US Military Cancer Institute
• Robert Martuza, MD, Member Board of Directors
Professor of Neurosurgery, Harvard Medical School, and Chief
of Neurosurgery, Massachusetts General Hospital
• Sherie Morrison, PhD, Member of Scientific Advisory Board
Chair, Dept of Microbiology, Immunology and Molecular
Genetics, UCLA
January 2010 13

14. Financial Position and Capitalization
• Cash: $1.4 Million (Dec 31st, 2009)
• Outstanding debt: $0
• Current burn rate: $600K/quarter
• Shares outstanding: 14.6 million
• Current share price: $1.00
• Current market cap: $14.6 million
• Options outstanding : 9.7 million; average weighted
average exercise price of $1.00
• Commitment from
Socius Capital: $10 million at market price
January 2010 14

15. Summary
• Well positioned to become a complete immune
solutions company targeting cancer
• Unique technology based on cancer stem cells
• Strong scientific and clinical expertise
• Strong IP position covering CSCs and MAbs
• 4 clinical trials planned in next 3 years targeting brain,
pancreatic, breast and ovarian cancers
• Additional partnering opportunities in 2010
• Potential for a 3‐5 X capital return to investors
January 2010 15